证券代码：601698 证券简称：中国卫通 公告编号：2025-013 中国卫通集团股份有限公司 关于使用自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 现金管理受托方：主要合作银行等金融机构。 ? 现金管理金额：最高额度不超过人民币 30 亿元，在上 述额度内，该部分资金可循环滚动使用。 ? 现金管理产品：安全性高、流动性好、有保本约定的 现金管理产品。 ? 现金管理期限：决议有效期为自公司第三届董事会第 十七次会议审议通过之日起至次年年度董事会召开日 前止。 ? 履行的审议程序：公司于 2025 年 3 月 31 日召开公司 第三届董事会第十七次会议，审议通过了《中国卫通 关于使用自有资金进行现金管理的议案》。 一、本次使用自有资金进行现金管理的基本情况 （一）管理目的 为提高资金使用效率和收益，合理利用自有资金，在保 证不影响公司后续卫星资源建设计划正常进行和公司正常 经营业务的前提下，利用自有资金进行现金管理，增加公司 收益，保障公司股东的利益。 （二）现金管理额度 公司 ...

Core Viewpoint - Xinghui Environmental Materials Co., Ltd. is set to hold its first extraordinary general meeting of shareholders in 2025 on April 11, 2025, to discuss several key proposals, including adjustments to credit limits and cash management strategies [1][2]. Company Announcements - The company reported a stock price of 20.61 yuan as of March 28, 2025, reflecting a 0.44% increase from the previous week, with a total market capitalization of 3.992 billion yuan [1]. - The company will adjust its comprehensive credit limit to no more than 3 billion yuan, up from 2.5 billion yuan, with authorization for the chairman to manage the distribution of this credit [2][4]. - The guarantee limit for subsidiaries will be increased from 1.5 billion yuan to 2 billion yuan, with various forms of guarantees permitted [2][4]. - The company plans to use up to 1.2 billion yuan of idle raised funds and up to 2.5 billion yuan of its own funds for cash management, with a focus on safe and liquid investment products [2][4]. Meeting Details - The extraordinary general meeting will take place at 2:30 PM on April 11, 2025, at the Shantou Free Trade Zone, with both on-site and online voting options available [1][3].

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 湖北济川药业股份有限公司 关于全资子公司利用闲置自有资金进行现金管理的公告 重要内容提示： ● 现金管理种类 ：安全性高、风险较低的理财产品或金融产品，包括但不限于银行、信托、基金、证 券公司或其他金融机构发行的产品等。 ● 现金管理额度及期限：合计不超过人民币45亿元（含本数）闲置自有资金，期限自董事会审议通过之 日起十二个月内。在上述额度及决议有效期内，资金可循环滚动使用。 ● 履行的审议程序：公司于2025年3月28日召开了第十届董事会第十三次会议和第十届监事会第十三次 会议，会议审议通过了《关于全资子公司利用闲置自有资金进行现金管理的议案》。 ● 特别风险提示：公司拟选择低风险投资品种的现金管理产品，但金融市场受宏观经济的影响较大，公 司将根据经济形势以及金融市场的变化适时适量地介入，但不排除该项投资受到市场波动的影响。 2025年3月28日，湖北济川药业股份有限公司（以下简称"公司"）召开了第十届董事会第十三次会议和 第十届监事会第十三次会议，会议审议通过了《关于全资子公司利用闲置自有资金进行现金管理的议 案》，相关情况如下： 一、使用闲置自有资 ...

Fundraising Overview - The company raised a total of RMB 525.36 million by issuing 22 million shares at RMB 23.88 per share, with a net amount of RMB 446.17 million after deducting issuance costs of RMB 79.19 million, which was deposited into a dedicated fundraising account on February 10, 2023 [1][2] - As of December 31, 2024, the balance in the fundraising account was RMB 4.27 million, with a total of RMB 44.62 million raised and utilized for various projects and working capital [2][3] Fund Utilization - The company allocated RMB 7.21 million for project investments and RMB 8 million for working capital, with an additional RMB 1.2 million from oversubscribed funds permanently supplementing working capital [2][3] - The total amount utilized for project investments reached RMB 10.30 million, while the cash management activities generated a net interest income of RMB 1.46 million [2][3] Fund Management - The company established a fundraising management system to ensure compliance with relevant regulations and protect investor interests, including a tripartite supervision agreement with banks and the sponsor [3][4] - As of December 31, 2024, the company had not used idle fundraising for temporary working capital and had engaged in cash management with a balance of RMB 24.65 million, primarily in high-security, liquid investment products [4][5] Project Status and Adjustments - The company approved the use of RMB 6.68 million of fundraising to replace pre-invested project funds and RMB 0.57 million for issuance costs [4][5] - The high-end optical lens intelligent manufacturing project and the R&D center upgrade project have been delayed, with the expected completion date adjusted to December 2026 due to market conditions and project progress [8][9] Compliance and Audit - The company has adhered to all relevant laws and regulations regarding fundraising usage, with no violations reported [10][11] - The sponsor confirmed that the management of fundraising and its usage complied with regulatory requirements, with no changes in the purpose of the funds that could harm shareholder interests [11]

Core Points - The supervisory board of Guangzhou Da'an Gene Co., Ltd. held its sixth meeting of the eighth session on March 27, 2025, where several key resolutions were passed [1][2][3] Group 1: Supervisory Board Resolutions - The 2024 Annual Supervisory Board Work Report was approved with a unanimous vote of 5 in favor [1] - The 2024 Annual Financial Settlement Proposal was approved, noting a significant decline in performance due to increased bad debt provisions and a decrease in the fair value of other non-current financial assets [2] - The 2024 Annual Report and its summary were approved, with the supervisory board confirming that the report accurately reflects the company's situation without any misleading statements [2][3] Group 2: Profit Distribution and Financial Management - The 2024 Profit Distribution Proposal was approved, indicating that the company will not distribute cash dividends or issue bonus shares due to negative net profits [3][5] - The 2024 Internal Control Evaluation Report was approved, confirming the effectiveness of the company's internal control system [5][6] - The proposal for expected related party transactions for 2025 was approved, with the supervisory board ensuring compliance with relevant laws and regulations [6][7] Group 3: Financial Management and Policy Changes - The proposal for using idle self-owned funds for cash management in 2025 was approved [7] - The proposal for changes in accounting policies was approved [7]

证券代码：688307 证券简称：中润光学 公告编号：2025-011 嘉兴中润光学科技股份有限公司 关于使用部分暂时闲置的募集资金及自有资金 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉兴中润光学科技股份有限公司（以下简称"公司"）于2025年3月28日分别 召开了第二届董事会第七次会议和第二届监事会第六次会议，分别审议通过了《关 于使用部分暂时闲置的募集资金及自有资金进行现金管理的议案》。根据决议， 在不影响公司募投项目正常实施进度的情况下，公司及子公司计划使用不超过人 民币3.00亿元（含本数）部分暂时闲置的募集资金及不超过人民币3.00亿元（含本 数）的自有资金进行现金管理，用于购买安全性高、流动性好、有保本约定的投 资产品（包括但不限于保本型理财产品、结构性存款、通知存款、定期存款、大 额存单等），使用期限自2024年度股东大会审议通过之日起12个月，在上述额度 内的资金可在投资期限内滚动使用，其中与募集资金相关的现金管理资金期满后 归还至公司募集资金专项账户。 在授权额度范围内，董事会 ...

证券代码：603286 证券简称：日盈电子 公告编号：2025-024 江苏日盈电子股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理额度及期限：江苏日盈电子股份有限公司（以下简称"公司"）拟 使用额度不超过人民币 18,000 万元（包含本数）的部分闲置自有资金进行现金 管理，期限为自公司本次董事会审议通过之日起至下一年度董事会召开之日止， 在上述额度内的资金可以循环滚动使用。 现金管理种类：包括但不限于银行、信托公司、证券公司、基金公司、期货 公司、保险资产管理机构、金融资产投资公司等资信状况及财务状况良好、无不 良诚信记录以及盈利能力强的合格专业理财机构发行的理财产品。 已履行的审议程序：本次现金管理事项已经公司 2025 年 3 月 27 日召开的 第五届董事会第三次会议及第五届监事会第三次会议审议通过，无需提交股东大 会审议。 特别风险提示：尽管公司拟使用部分闲置自有资金在授权额度范围内购买资 信状况及财务状况良好、无不良诚信记录以及盈利能力强的合格专业理财机构发 行的理财产品，但 ...

Group 1 - The core viewpoint of the article is the performance and operational details of Rongcheng Accounting Firm, including its audit services and financial metrics for 2023 [2][4][12] - As of December 31, 2024, Rongcheng Accounting Firm has 212 partners and 1,552 registered accountants, with 781 having signed audit reports for securities services [1] - The total audited revenue for Rongcheng Accounting Firm in 2023 was approximately 287.22 million yuan, with audit business revenue at about 274.87 million yuan and securities and futures business revenue at approximately 149.86 million yuan [2] Group 2 - Rongcheng Accounting Firm undertook the audit of 394 listed companies for their 2023 annual reports, with total audit fees amounting to approximately 48.84 million yuan [2] - The firm has a strong client base in various industries, primarily in manufacturing and information technology services [2] - The firm has purchased professional liability insurance with a cumulative compensation limit of no less than 200 million yuan [3] Group 3 - In the past three years, Rongcheng Accounting Firm has faced no criminal or administrative penalties, but has received 14 supervisory measures and 6 self-regulatory measures [5] - The firm has been involved in a civil lawsuit regarding securities false statements related to LeEco, with a judgment requiring it to share liability for losses with LeEco [4] Group 4 - The audit fees for 2024 for the company are set at 848,000 yuan, remaining stable compared to the previous period [11] - The audit committee has conducted a thorough review of Rongcheng Accounting Firm's qualifications and has recommended its reappointment for the 2025 audit [12][13] Group 5 - The company has reported a total of 38.32 million yuan raised from its initial public offering, with a net amount of approximately 33.04 million yuan after deducting issuance costs [17] - As of December 31, 2024, the company has utilized approximately 39.85 million yuan of the raised funds, with a remaining balance of about 10.23 million yuan [18] Group 6 - The company has established a fundraising management system to ensure compliance with regulations and protect investor interests [19] - The company has signed a tripartite supervision agreement for the management of raised funds, ensuring all parties fulfill their responsibilities [20]

Investment Overview - The company plans to utilize idle self-owned funds for cash management to increase investment returns, with a maximum daily balance of 700 million yuan allocated for purchasing financial products [1] - The financial products will be of medium to low risk, with a focus on high safety and liquidity, ensuring that principal-protected products have a maturity of no more than one year, while non-principal-protected products will have a maturity of less than 90 days [1] Approval Process - The investment proposal has been approved by the company's board and will be submitted for review at the 2024 annual shareholders' meeting [2] Risk Analysis and Control Measures - The company acknowledges potential market volatility risks affecting the investment but has established internal control measures to manage and mitigate these risks [2] - The company will adhere to relevant regulations and guidelines to ensure the safety of the investment funds and will take timely actions to address any adverse factors [2] Impact on the Company - The investment in financial products is expected to enhance the efficiency and returns of the company's idle funds without impacting its liquidity or operational funding needs [2] Accounting Policies - The company will follow the relevant accounting standards for financial instruments to ensure proper accounting and disclosure of the investment activities [2]

Core Viewpoint - The company intends to utilize part of its idle raised funds and idle self-owned funds for cash management, ensuring that it does not affect the normal operation of fundraising investment projects and aims to improve fund utilization efficiency and returns for shareholders [1][4][10]. Fundraising Situation - The company successfully issued 17 million shares at a price of 44.48 RMB per share, raising a total of 756.16 million RMB, with a net amount of 675.72 million RMB after deducting related issuance costs [1][2]. Fund Usage and Idle Reasons - The company has adjusted its fundraising investment projects, reallocating funds to a new project for producing 300 tons of A-40 (Atorvastatin Calcium) raw materials, with a total investment of 694.85 million RMB [2][3]. Previous Cash Management - The company approved the use of up to 100 million RMB of idle raised funds and 50 million RMB of excess raised funds for cash management, focusing on low-risk, high-liquidity financial products [3][4]. Current Cash Management Plan - The company plans to use up to 300 million RMB of idle raised funds and 300 million RMB of idle self-owned funds for cash management, with a maximum investment period of 12 months [5][6][9]. Decision Approval Process - The independent directors and the board of supervisors have reviewed and approved the cash management proposals, confirming compliance with relevant regulations and ensuring no harm to shareholder interests [8][10].